deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT05281510

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

A Phase 2a Study to Evaluate the Safety and Tolerability of a Regimen of Dual Anti-HIV Envelope Antibodies, VRC07-523LS and CAP256V2LS, in a Sequential Regimen With a TLR7 Agonist, Vesatolimod, in Early Antiretroviral-Treated HIV-1 Clade C-Infected Women

Sponsor: Gilead Sciences

Conditions HIV-1-infection
Interventions CAP256V2LS VRC07523LS Vesatolimod
Updated 22 times since 2022 Last updated: Dec 24, 2025 Started: Jun 9, 2022 Primary completion: Jan 16, 2025 Completion: Jan 16, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on HIV-1-infection, this trial is completed. The trial is conducted by Gilead Sciences and has accumulated 22 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Feb 2026 · 12 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

22 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

  2. Feb 2025 — Feb 2026 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 17 earlier versions

  1. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  3. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  4. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  5. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  6. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  7. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  8. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  9. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  10. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  11. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  12. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  13. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  14. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  15. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. May 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

  17. Apr 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations